Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02337491 |
| Title | Pembrolizumab +/- Bevacizumab for Recurrent GBM |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | United States | Details | |
| University of California, San Francisco | San Francisco | California | 94143-0372 | United States | Details | |
| Massachusetts General Hospital | Boston | Massachusetts | 02113 | United States | Details | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| Memorial Sloan-Kettering Cancer | New York | New York | 10021 | United States | Details | |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States | Details | |
| UT, MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | United States | Details |